• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胶质瘤中的三级淋巴结构:对肿瘤免疫和进展的影响

Tertiary lymphoid structures in gliomas: impact on tumour immunity and progression.

作者信息

Chen Jiatong, Yang Yuechao, Luan Shuang, Xu Wenhao, Gao Yang

机构信息

Shanghai Medical College, Fudan University, Shanghai, China.

Department of Neurosurgery, Fudan University Shanghai Cancer Center, Shanghai, China.

出版信息

J Transl Med. 2025 May 9;23(1):528. doi: 10.1186/s12967-025-06510-6.

DOI:10.1186/s12967-025-06510-6
PMID:40346572
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12065291/
Abstract

Tertiary lymphoid structures (TLSs) are ectopic lymphoid formations that develop in chronically inflamed tissues, including various solid tumours. In the context of gliomas, the presence of TLSs has recently attracted considerable attention because of their potential implications in tumour immunology and therapy. The tumour immune microenvironment (TIME) plays a crucial role in cancer progression, and tumour-infiltrating immune cells (TILs) are key players in this environment. These immune cell aggregates, known as TLSs, display distinct characteristics across different solid tumours. However, central nervous system (CNS) tumours are highly heterogeneous, and the immune environment within these tumours is often more deficient than that of peripheral tissue tumours. This leads to differences in the formation and function of TLSs in CNS tumours. These variations are particularly relevant in the context of glioma immunotherapy and could have important implications for treatment strategies. This review focuses on the composition and function of TLSs, examines the complexity of the glioblastoma (GBM) immune microenvironment, and highlights the unique characteristics of TLSs in GBM, providing new theoretical insights and practical foundations for targeting TLSs in glioma immunotherapy.

摘要

三级淋巴结构(TLSs)是在包括各种实体瘤在内的慢性炎症组织中形成的异位淋巴组织。在胶质瘤的背景下,TLSs的存在最近因其在肿瘤免疫学和治疗中的潜在影响而备受关注。肿瘤免疫微环境(TIME)在癌症进展中起着关键作用,肿瘤浸润免疫细胞(TILs)是这一环境中的关键参与者。这些被称为TLSs的免疫细胞聚集体在不同实体瘤中表现出不同的特征。然而,中枢神经系统(CNS)肿瘤高度异质性,这些肿瘤内的免疫环境往往比外周组织肿瘤更缺乏。这导致了CNS肿瘤中TLSs的形成和功能存在差异。这些差异在胶质瘤免疫治疗中尤为相关,可能对治疗策略具有重要意义。本综述重点关注TLSs的组成和功能,探讨胶质母细胞瘤(GBM)免疫微环境的复杂性,并强调GBM中TLSs的独特特征,为胶质瘤免疫治疗中靶向TLSs提供新的理论见解和实践基础。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/28a1e4ef6a17/12967_2025_6510_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/6b9b5a13abd7/12967_2025_6510_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/a888091de85a/12967_2025_6510_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/49ac355963ac/12967_2025_6510_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/28a1e4ef6a17/12967_2025_6510_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/6b9b5a13abd7/12967_2025_6510_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/a888091de85a/12967_2025_6510_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/49ac355963ac/12967_2025_6510_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10fe/12065291/28a1e4ef6a17/12967_2025_6510_Fig4_HTML.jpg

相似文献

1
Tertiary lymphoid structures in gliomas: impact on tumour immunity and progression.胶质瘤中的三级淋巴结构:对肿瘤免疫和进展的影响
J Transl Med. 2025 May 9;23(1):528. doi: 10.1186/s12967-025-06510-6.
2
Tertiary lymphoid structures in the era of cancer immunotherapy.癌症免疫治疗时代的三级淋巴结构。
Nat Rev Cancer. 2019 Jun;19(6):307-325. doi: 10.1038/s41568-019-0144-6.
3
Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma.三级淋巴结构和肿瘤浸润淋巴细胞在胆管癌中的比较影响
J Immunother Cancer. 2025 Jan 27;13(1):e010173. doi: 10.1136/jitc-2024-010173.
4
Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.三级淋巴结构与癌症免疫疗法:从实验台到病床旁
Med. 2025 Jan 10;6(1):100546. doi: 10.1016/j.medj.2024.10.023.
5
Tertiary lymphoid structures and their therapeutic implications in cancer.三级淋巴结构及其在癌症中的治疗意义。
Cell Oncol (Dordr). 2024 Oct;47(5):1579-1592. doi: 10.1007/s13402-024-00975-1. Epub 2024 Aug 12.
6
Integrated analysis of tertiary lymphoid structures and immune infiltration in ccRCC microenvironment revealed their clinical significances: a multicenter cohort study.三阴性乳腺癌微环境中三级淋巴结构和免疫浸润的综合分析揭示了它们的临床意义:一项多中心队列研究。
J Immunother Cancer. 2024 Jun 21;12(6):e008613. doi: 10.1136/jitc-2023-008613.
7
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma.肿瘤内三级淋巴结构与肝细胞癌早期复发风险低相关。
J Hepatol. 2019 Jan;70(1):58-65. doi: 10.1016/j.jhep.2018.09.003. Epub 2018 Sep 11.
8
Role of tertiary lymphoid structures and B cells in clinical immunotherapy of gastric cancer.三级淋巴结构和B细胞在胃癌临床免疫治疗中的作用。
Front Immunol. 2025 Jan 7;15:1519034. doi: 10.3389/fimmu.2024.1519034. eCollection 2024.
9
Distinct maturity and spatial distribution of tertiary lymphoid structures in head and neck squamous cell carcinoma: implications for tumor immunity and clinical outcomes.头颈部鳞状细胞癌中三级淋巴结构的不同成熟度和空间分布:对肿瘤免疫和临床结果的影响
Cancer Immunol Immunother. 2025 Feb 11;74(3):107. doi: 10.1007/s00262-025-03952-1.
10
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.白细胞介素-33激活的2型固有淋巴细胞在胰腺癌中诱导三级淋巴结构形成。
Nature. 2025 Feb;638(8052):1076-1084. doi: 10.1038/s41586-024-08426-5. Epub 2025 Jan 15.

引用本文的文献

1
Dural ectopic lymphatic structures accumulate during aging and exhibit dysregulation in neurodegenerative diseases.硬脑膜异位淋巴结构在衰老过程中会累积,并在神经退行性疾病中表现出失调。
Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2425081122. doi: 10.1073/pnas.2425081122. Epub 2025 Aug 12.

本文引用的文献

1
Advances in nanoplatform-based multimodal combination therapy activating STING pathway for enhanced anti-tumor immunotherapy.基于纳米平台的多模态联合疗法激活STING通路以增强抗肿瘤免疫治疗的进展。
Colloids Surf B Biointerfaces. 2025 Jun;250:114573. doi: 10.1016/j.colsurfb.2025.114573. Epub 2025 Feb 17.
2
Tertiary Lymphoid Structures Are Associated with Enhanced Macrophage Activation and Immune Checkpoint Expression and Predict Outcome in Cervical Cancer.三级淋巴结构与巨噬细胞活化增强和免疫检查点表达相关,并可预测宫颈癌的预后。
Cancer Immunol Res. 2025 May 2;13(5):712-728. doi: 10.1158/2326-6066.CIR-24-0979.
3
Hunting glioblastoma recurrence: glioma stem cells as retrospective targets.
追踪胶质母细胞瘤复发:胶质瘤干细胞作为回顾性靶点。
Am J Physiol Cell Physiol. 2025 Mar 1;328(3):C1045-C1061. doi: 10.1152/ajpcell.00344.2024. Epub 2025 Jan 16.
4
Immunotherapy for glioblastoma: current state, challenges, and future perspectives.胶质母细胞瘤的免疫治疗:现状、挑战与未来展望。
Cell Mol Immunol. 2024 Dec;21(12):1354-1375. doi: 10.1038/s41423-024-01226-x. Epub 2024 Oct 15.
5
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.疾病中的三级淋巴结构:免疫机制与治疗进展。
Signal Transduct Target Ther. 2024 Aug 28;9(1):225. doi: 10.1038/s41392-024-01947-5.
6
Toll-like receptor agonists promote the formation of tertiary lymphoid structure and improve anti-glioma immunity.Toll样受体激动剂促进三级淋巴结构的形成并增强抗胶质瘤免疫。
Neuro Oncol. 2025 Jan 12;27(1):140-154. doi: 10.1093/neuonc/noae167.
7
Spatial dynamics of tertiary lymphoid aggregates in head and neck cancer: insights into immunotherapy response.头颈部癌症中三级淋巴滤泡的空间动态:免疫治疗反应的见解。
J Transl Med. 2024 Jul 24;22(1):677. doi: 10.1186/s12967-024-05409-y.
8
Tertiary lymphoid structures: new immunotherapy biomarker.三级淋巴结构:新的免疫治疗标志物。
Front Immunol. 2024 Jul 4;15:1394505. doi: 10.3389/fimmu.2024.1394505. eCollection 2024.
9
Tumor-associated tertiary lymphoid structures in cancer: implications for immunotherapy.肿瘤相关的三级淋巴结构在癌症中的作用:对免疫治疗的启示。
Expert Rev Clin Immunol. 2024 Aug;20(8):839-847. doi: 10.1080/1744666X.2024.2380892. Epub 2024 Jul 16.
10
Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.基于三级淋巴结构和肿瘤芽生的人工智能综合分析预测三阴性乳腺癌的生存情况
Cancer. 2024 Apr 15;130(S8):1499-1512. doi: 10.1002/cncr.35261. Epub 2024 Feb 29.